HRP20100210T1 - Upotreba alopurinola u liječenju eritrodisestezije dlana i stopala - Google Patents

Upotreba alopurinola u liječenju eritrodisestezije dlana i stopala Download PDF

Info

Publication number
HRP20100210T1
HRP20100210T1 HR20100210T HRP20100210T HRP20100210T1 HR P20100210 T1 HRP20100210 T1 HR P20100210T1 HR 20100210 T HR20100210 T HR 20100210T HR P20100210 T HRP20100210 T HR P20100210T HR P20100210 T1 HRP20100210 T1 HR P20100210T1
Authority
HR
Croatia
Prior art keywords
allopurinol
erythrodysesthesia
treatment
intended
caused
Prior art date
Application number
HR20100210T
Other languages
English (en)
Croatian (hr)
Inventor
Rodemer Yolanda
Original Assignee
Nobera Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP06011432A external-priority patent/EP1862166A1/en
Application filed by Nobera Pharma filed Critical Nobera Pharma
Publication of HRP20100210T1 publication Critical patent/HRP20100210T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HR20100210T 2006-06-01 2007-05-31 Upotreba alopurinola u liječenju eritrodisestezije dlana i stopala HRP20100210T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06011432A EP1862166A1 (en) 2006-06-01 2006-06-01 Use of allopurinol for the treatment of palmar plantar erythrodysesthesia
EP07107744 2007-05-08
PCT/EP2007/055367 WO2007138103A1 (en) 2006-06-01 2007-05-31 Use of allopurinol for the treatment of palmar plantar erythrodysesthesia

Publications (1)

Publication Number Publication Date
HRP20100210T1 true HRP20100210T1 (hr) 2010-05-31

Family

ID=38512579

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20100210T HRP20100210T1 (hr) 2006-06-01 2007-05-31 Upotreba alopurinola u liječenju eritrodisestezije dlana i stopala

Country Status (21)

Country Link
US (3) US7973046B2 (pt)
EP (1) EP2035006B1 (pt)
JP (3) JP5028480B2 (pt)
KR (1) KR101471022B1 (pt)
AT (1) ATE457729T1 (pt)
AU (1) AU2007267069B2 (pt)
CA (1) CA2654270C (pt)
CY (1) CY1110336T1 (pt)
DE (1) DE602007004849D1 (pt)
DK (1) DK2035006T3 (pt)
ES (1) ES2341379T3 (pt)
HR (1) HRP20100210T1 (pt)
IL (1) IL195472A (pt)
MX (1) MX2008015266A (pt)
NZ (1) NZ573248A (pt)
PL (1) PL2035006T3 (pt)
PT (1) PT2035006E (pt)
RS (1) RS51252B (pt)
RU (1) RU2438673C2 (pt)
SI (1) SI2035006T1 (pt)
WO (1) WO2007138103A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2246057A1 (en) * 2009-04-29 2010-11-03 Nobera Pharma, S.L. Use of allopurinol for the treatment of hand foot skin reaction
JP2013508295A (ja) 2009-10-16 2013-03-07 デューク・ユニヴァーシティ 薬物誘発性手足症候群を治療するための組成物および方法
EP2368549A1 (en) 2010-03-25 2011-09-28 BioAlliance Pharma Treating hand-foot syndrome and related pathologies using clonidine or its derivatives
JP4983989B2 (ja) * 2010-03-31 2012-07-25 小野薬品工業株式会社 手足症候群の予防および治療剤
US8729056B2 (en) 2010-03-31 2014-05-20 Ono Pharmaceutical Co., Ltd. Preventive and/or therapeutic agent of hand-foot syndrome
JP4761000B1 (ja) * 2010-11-08 2011-08-31 小野薬品工業株式会社 手足症候群の予防および／または治療剤
US9259343B2 (en) 2012-07-06 2016-02-16 Newman Technologies LLC Device for mitigating plantar fasciitis
EP2712613B1 (en) * 2012-09-28 2017-02-08 Pharmadab d.o.o. Vitamin K1 and uses thereof
WO2017168416A1 (en) * 2016-03-28 2017-10-05 Vidac Pharma Ltd. Stable pharmaceutical compositions for topical administration and uses thereof
JP2021506958A (ja) 2017-12-13 2021-02-22 オンクォリティ ファーマシューティカルズ チャイナ エルティーディーＯｎｑｕａｌｉｔｙ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｈｉｎａ Ｌｔｄ． Ｅｇｆｒ阻害に関連する疾患を予防又は治療する方法
KR102831159B1 (ko) 2018-04-16 2025-07-07 온퀄리티 파마슈티컬스 차이나 리미티드 암 치료의 부작용을 예방하거나 치료하기 위한 방법
RU2722396C2 (ru) * 2018-07-11 2020-05-29 Федеральное государственное бюджетное учреждение дополнительного профессионального образования "Центральная государственная медицинская академия" Управления делами Президента Российской Федерации (ФГБУ ДПО "ЦГМА") Способ лечения пальмарно-плантарной эритродизестезии

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3011A (en) * 1843-03-21 Improvement in water-wheels
ATE66147T1 (de) 1987-02-13 1991-08-15 Allergan Pharma Verwendung von pteridinen und/oder purinen oder eines xanthinoxidase-hemmers zur herstellung eines arzneimittels zur behandlung von genetisch bedingten degenerativen netzhauterkrankungen.
JPH03106817A (ja) 1989-09-20 1991-05-07 Nippon Kayaku Co Ltd アロプリノール製剤
JPH066700A (ja) 1992-06-22 1994-01-14 Fujitsu General Ltd ハイビジョン受像機
WO1994005293A1 (en) 1992-09-04 1994-03-17 Aws Shakir Mustafa Salim Skin treatment compositions containing dimethylsulphone and allopurinol or oxypurinol
GB9218711D0 (en) * 1992-09-04 1992-10-21 Salim Aws S M Skin cancer treatment
JP3106817B2 (ja) 1993-11-02 2000-11-06 富士電機株式会社 漏電遮断器
US6284234B1 (en) * 1998-08-04 2001-09-04 Johnson & Johnson Consumer Companies, Inc. Topical delivery systems for active agents
US6060083A (en) 1999-04-01 2000-05-09 Topical Technologies, Inc. Topical DMSO treatment for palmar-plantar erythrodysethesia
AU2001267533A1 (en) 2000-06-20 2002-01-02 Henkel Kommanditgesellschaft Auf Aktien Structure-improving hair care agents
EP1609468A3 (en) 2000-11-22 2006-01-25 Rxkinetix, Inc. A composition on the basis of a sulfur-containing antioxidant and its use for the manufacture of a medicament for treating mucositis
US7544348B2 (en) 2001-02-15 2009-06-09 Access Pharmaceuticals, Inc. Liquid formulations for the prevention and treatment of mucosal diseases and disorders
EP1455888B1 (en) * 2001-08-29 2009-04-29 PharmaKodex Limited Topical administration device
EP1461033B1 (en) 2001-11-29 2013-02-27 Sound Pharmaceuticals Incorporated Methods and compositions for ameliorating the undesirable effects of chemotherapy
DE10200578A1 (de) * 2002-01-09 2003-07-10 Roehm Gmbh Haft- und Bindemittel für dermale oder transdermale Therapiesysteme
US6979688B2 (en) * 2002-02-12 2005-12-27 Ford John P Treatment method against side-effects of chemotherapy
US20040214215A1 (en) * 2003-03-07 2004-10-28 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
CA2528359A1 (en) 2003-06-11 2004-12-23 Novacea, Inc. Treatment of cancer with active vitamin d compounds in combination with radiotherapeutic agents and treatments
CA2528378A1 (en) 2003-06-11 2004-12-23 Novacea, Inc. Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
US20050148910A1 (en) 2003-12-24 2005-07-07 Gregory Skover Apparatus having a skin-contactable element containing an agent
CA2557814A1 (en) * 2004-03-01 2005-09-15 Lumen Therapeutics, Llc Compositions and methods for treating diseases
JP4405326B2 (ja) 2004-06-28 2010-01-27 株式会社東芝 ランドリー機器
EP1791535B1 (en) * 2004-09-17 2008-07-30 BioMAS Ltd. Novel tellurium compounds and their use as immunomodulators

Also Published As

Publication number Publication date
CA2654270A1 (en) 2007-12-06
AU2007267069A1 (en) 2007-12-06
US20140011820A1 (en) 2014-01-09
JP2009542581A (ja) 2009-12-03
US8557829B2 (en) 2013-10-15
MX2008015266A (es) 2009-02-10
DE602007004849D1 (de) 2010-04-01
IL195472A0 (en) 2011-08-01
KR20090031697A (ko) 2009-03-27
ES2341379T3 (es) 2010-06-18
IL195472A (en) 2012-04-30
JP2012180370A (ja) 2012-09-20
NZ573248A (en) 2011-01-28
DK2035006T3 (da) 2010-04-19
EP2035006B1 (en) 2010-02-17
AU2007267069B2 (en) 2011-08-11
US20110224237A1 (en) 2011-09-15
JP5028480B2 (ja) 2012-09-19
CY1110336T1 (el) 2015-01-14
JP5389980B2 (ja) 2014-01-15
CA2654270C (en) 2014-05-13
US20090306097A1 (en) 2009-12-10
RU2008152341A (ru) 2010-07-20
US7973046B2 (en) 2011-07-05
JP2014028851A (ja) 2014-02-13
EP2035006A1 (en) 2009-03-18
PT2035006E (pt) 2010-04-22
RU2438673C2 (ru) 2012-01-10
KR101471022B1 (ko) 2014-12-09
RS51252B (sr) 2010-12-31
ATE457729T1 (de) 2010-03-15
SI2035006T1 (sl) 2010-04-30
PL2035006T3 (pl) 2010-07-30
WO2007138103A1 (en) 2007-12-06

Similar Documents

Publication Publication Date Title
HRP20100210T1 (hr) Upotreba alopurinola u liječenju eritrodisestezije dlana i stopala
JP2009542581A5 (pt)
BRPI1014433A2 (pt) "derivado de um composto ou um sal farmaceuticamente aceitável, composição farmacêutica ou nutracêutica, e métodos para tratar uma condição, para reduzir o desenvolvimento à tolerância a medicamentos vasodilatadores, para estimular a função mitocondrial em células, para melhorar a estrutura ou a função muscular em um animal e os efeitos mitocondriais associados com exercício em um animal, para intensificar a capacidade de exercício em um animal, a saúde e a função muscular, e a recuperação de músculos de atividade vigorosa ou do dano associado com atividade vigorosa ou sustentada em um animal, e, usos de epicatequina ou um derivado de epicatequina, de nicorandil ou um derivado de nicorandil e suas combinações."
BRPI0906181A2 (pt) "método para tratamento de uma disfunção hiperproliferativa, composição farmacêutica, uso de uma combinação terapêutica na fabricação de um medicamento para o tratamento de câncer, artigo de fabricação para tratamento de uma disfunção hiperproliferativa, método para determinação de compostos a serem usados em combinação para o tratamento de câncer e método para determinação de uma combinação terapêutica a ser usada para o tratamento de câncer"
FI3504187T3 (fi) Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten
HRP20120798T1 (hr) Kappa-opijatni agonisti za lijeäśenje dijareja-predominantnog i naizmjeniäśnog sindroma iritabilnog crijeva
JP2016106150A5 (pt)
JP2010525050A5 (pt)
BR112014009713A2 (pt) administração transdérmica de agentes bioativos de alta viscosidade
JP2014516942A5 (pt)
HRP20140592T1 (hr) Poboljšani medicinski pripravci koji sadrže buprenorfin i naltrekson
SI2889033T1 (en) Treatment of negative symptoms of schizophrenia with (R) -7-chloro-N- (chonylidin-3-yl) benzo (B) thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
EP4442321A3 (en) Methods of treating sjögren's syndrome using a bruton's tyrosine kinase inhibitor
RU2011148355A (ru) Применение аллопуринола для ладонно-родошвенного синдрома
AR072951A1 (es) Uso de dronedarona o una sal aceptable farmaceuticamente de esta, para la preparacion de un medicamento para regular el nivel de potasio en la sangre
HRP20231448T1 (hr) Primjena delgocitiniba za liječenje kroničnog ekcema ruku
NZ584968A (en) Novel antiretroviral combination comprising ritonavir and atazanavir
BRPI0918593A2 (pt) composição farmacêutica para uso no tratamento de infecções transmitidas sexualmente
RU2018125252A (ru) Синергическая комбинация пирролидонкарбоновой кислоты и/или ее солей и гиалуроновой кислоты и/или ее солей для применения в лечении и/или профилактике сухости и раздражения слизистых оболочек, и связанные фармацевтические композиции
JP2017511307A5 (pt)
IL275091B2 (en) Methods for treating gaucher disease
HRP20151241T1 (hr) Upotreba s-adenozilmetionina (sam) i superoksid-dismutaze (sod) za pripravu lijekova za lijeäśenje alzheimerove bolesti
WO2007144889A3 (en) Treatment of neurofibromatosis
JP2012530709A5 (pt)
BRPI0602179A (pt) composição farmacêutica compreendendo ciclobenzaprina e aceclofenaco em combinação